tradingkey.logo
tradingkey.logo
Search

Calidi Biotherapeutics Inc

CLDI
Add to Watchlist
1.640USD
+0.177+11.87%
Close 07-31 16:00ETQuotes delayed by 15 min
11.33MMarket Cap
LossP/E TTM

CLDI Income Statement

You can find the annual or quarterly income statement of Calidi Biotherapeutics Inc here for insights into the performance and operational efficiency of Calidi Biotherapeutics Inc.
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
Total revenue
----
----
----
----
----
----
----
----
----
--0.00
--0.00
--0.00
-100.00%0.00
-100.00%0.00
--0.00
--0.00
--45.00K
--405.00K
Revenue
----
----
----
----
----
----
----
----
----
--0.00
--0.00
--0.00
-100.00%0.00
-100.00%0.00
--0.00
--0.00
--45.00K
--405.00K
Cost of revenue
----
----
----
----
----
----
----
----
----
--0.00
--0.00
--0.00
-100.00%0.00
-100.00%0.00
--0.00
--0.00
--14.00K
--50.00K
Operating expenses
-17.29%4.19M
10.93%4.47M
-3.41%5.05M
-1.87%5.66M
-25.03%5.06M
-59.00%4.03M
-27.63%5.23M
-11.70%5.77M
24.71%6.75M
109.47%9.82M
3.36%7.22M
49.18%6.54M
-23.93%5.41M
44.65%4.69M
--6.99M
--4.38M
--7.12M
--3.24M
R&D expenses
6.68%2.59M
29.92%2.36M
9.66%2.36M
19.66%2.59M
-11.59%2.42M
-54.14%1.81M
-33.77%2.15M
-31.79%2.17M
4.61%2.74M
74.90%3.96M
67.15%3.25M
114.08%3.18M
67.54%2.62M
81.62%2.26M
--1.94M
--1.48M
--1.56M
--1.25M
Depreciation, depletion, and amortization
326.00%426.00K
331.63%423.00K
318.63%427.00K
610.00%710.00K
-1.96%100.00K
-1.01%98.00K
17.24%102.00K
-11.50%100.00K
9.68%102.00K
1.02%99.00K
40.32%87.00K
135.42%113.00K
78.85%93.00K
104.17%98.00K
--62.00K
--48.00K
--52.00K
--48.00K
Operating profit
17.29%-4.19M
-10.93%-4.47M
3.41%-5.05M
1.87%-5.66M
25.03%-5.06M
59.00%-4.03M
27.63%-5.23M
11.70%-5.77M
-24.71%-6.75M
-109.47%-9.82M
-3.36%-7.22M
-49.18%-6.54M
23.44%-5.41M
-65.30%-4.69M
---6.99M
---4.38M
---7.07M
---2.84M
Net non-operating interest income (expenses)
Non-operating interest expense
-47.22%38.00K
-76.00%42.00K
-82.33%41.00K
-80.95%52.00K
-71.54%72.00K
-21.17%175.00K
-28.40%232.00K
-10.78%273.00K
16.59%253.00K
126.53%222.00K
1017.24%324.00K
1600.00%306.00K
1569.23%217.00K
58.06%98.00K
--29.00K
--18.00K
--13.00K
--62.00K
Gains from sale of securities
----
--244.00K
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
Special income (expenses)
37.14%48.00K
79.17%86.00K
-126.32%-100.00K
-120.00%-19.00K
117.59%35.00K
-96.07%48.00K
-92.16%380.00K
102.47%95.00K
86.85%-199.00K
141.22%1.22M
192.52%4.85M
-2189.88%-3.85M
-131.35%-1.51M
-398.32%-2.96M
--1.66M
---168.00K
---654.00K
---594.00K
Other non-operating income (expenses)
82.50%73.00K
1362.50%117.00K
125.00%18.00K
-111.52%-22.00K
335.29%40.00K
-98.64%8.00K
-98.83%8.00K
110.57%191.00K
-102.48%-17.00K
4638.46%590.00K
17025.00%685.00K
-60333.33%-1.81M
68500.00%686.00K
-316.67%-13.00K
--4.00K
--3.00K
--1.00K
--6.00K
Income before tax
18.88%-4.10M
2.03%-4.06M
-1.99%-5.17M
0.03%-5.76M
29.94%-5.06M
49.65%-4.14M
-151.86%-5.07M
53.92%-5.76M
-11.81%-7.22M
-6.10%-8.23M
62.40%-2.01M
-173.76%-12.50M
16.54%-6.46M
-122.58%-7.76M
---5.35M
---4.56M
---7.74M
---3.49M
Income tax
33.33%4.00K
-166.67%-2.00K
1100.00%10.00K
-50.00%4.00K
-25.00%3.00K
200.00%3.00K
-109.09%-1.00K
100.00%8.00K
0.00%4.00K
0.00%-3.00K
1000.00%11.00K
-63.64%4.00K
100.00%4.00K
-200.00%-3.00K
--1.00K
--11.00K
--2.00K
--3.00K
Income after tax
18.85%-4.11M
2.15%-4.06M
-2.21%-5.18M
0.10%-5.76M
29.94%-5.06M
49.59%-4.15M
-150.44%-5.07M
53.87%-5.77M
-11.81%-7.22M
-6.10%-8.23M
62.20%-2.02M
-173.19%-12.50M
16.51%-6.46M
-122.30%-7.76M
---5.36M
---4.58M
---7.74M
---3.49M
Net income from continuous operations
18.85%-4.11M
2.15%-4.06M
-2.21%-5.18M
0.10%-5.76M
29.94%-5.06M
49.59%-4.15M
-150.44%-5.07M
53.87%-5.77M
-11.81%-7.22M
-6.10%-8.23M
62.20%-2.02M
-173.19%-12.50M
16.51%-6.46M
-122.30%-7.76M
---5.36M
---4.58M
---7.74M
---3.49M
Net Income attributable to non-controlling interests
506.58%309.00K
94.12%-3.00K
-113.33%-32.00K
---46.00K
---76.00K
---51.00K
---15.00K
----
----
----
----
----
----
----
----
----
----
----
Net income attributable to controlling interests
11.41%-4.42M
1.00%-4.06M
-114.13%-10.82M
23.16%-5.71M
30.99%-4.99M
50.21%-4.10M
-149.70%-5.05M
40.50%-7.44M
-11.81%-7.22M
-6.10%-8.23M
62.20%-2.02M
-173.19%-12.50M
16.51%-6.46M
-122.30%-7.76M
---5.36M
---4.58M
---7.74M
---3.49M
Net income attributable to common shareholders
11.41%-4.42M
1.00%-4.06M
-114.13%-10.82M
23.16%-5.71M
30.99%-4.99M
50.21%-4.10M
-149.70%-5.05M
40.50%-7.44M
-11.81%-7.22M
-6.10%-8.23M
62.20%-2.02M
-173.19%-12.50M
16.51%-6.46M
-122.30%-7.76M
---5.36M
---4.58M
---7.74M
---3.49M
Basic earnings per share
-132.78%-0.43
-112.52%-0.57
-241.42%-2.21
85.77%-1.99
90.94%-0.18
82.57%-0.27
-45.06%-0.65
-407.57%-13.96
-42.94%-2.03
9.93%-1.54
62.21%-0.45
-173.18%-2.75
16.51%-1.42
-122.30%-1.71
---1.18
---1.01
---1.70
---0.77
Diluted earnings per share
-132.78%-0.43
-112.52%-0.57
-241.42%-2.21
85.77%-1.99
90.94%-0.18
82.57%-0.27
-45.06%-0.65
-407.57%-13.96
-42.94%-2.03
9.93%-1.54
62.21%-0.45
-173.18%-2.75
16.51%-1.42
-122.30%-1.71
---1.18
---1.01
---1.70
---0.77
Dividend per share
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
Currency unit
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
Audit opinions
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----

FAQs

How do I read Calidi Biotherapeutics Inc's income statement on TradingKey?

Start with total revenue, then review cost of revenue, gross profit, operating expenses, operating profit, income before tax, net income, and EPS. Revenue shows the scale of the business, while margins and profit lines show whether that revenue is being converted into earnings efficiently.

What is the difference between quarterly and annual income statements?

A quarterly income statement shows performance for a three-month fiscal period, while an annual income statement summarizes the full fiscal year. Quarterly data is useful for tracking recent momentum and seasonality, while annual data is better for judging long-term growth, profitability, and business cycles.

What does YOY mean on the income statement page?

YOY means year over year. It compares a financial metric with the same period in the previous year, such as this quarter's revenue versus revenue in the same quarter last year. YOY comparison helps investors see growth trends while reducing the impact of normal seasonal changes.

Which income statement metrics matter most when analyzing CLDI stock?

Important metrics include revenue growth, gross profit, gross margin, operating profit, operating margin, net income, EPS, R&D expenses, SG&A expenses, and tax expense. Investors usually look at these together to judge whether the company is growing, controlling costs, and improving profitability.

What was Calidi Biotherapeutics Inc's net income for the year?

Calidi Biotherapeutics Inc posted -25.58M in net income for fiscal year 2025.

How much net income did Calidi Biotherapeutics Inc post in the last quarter?

Calidi Biotherapeutics Inc reported -4.42M in net income for the latest quarter。

What was Calidi Biotherapeutics Inc's annual operating profit?

Calidi Biotherapeutics Inc's operating income was -20.24M for fiscal year 2025.

How is EPS related to the income statement?

EPS, or earnings per share, is based on net income divided by the number of shares outstanding. It helps investors understand how much profit the company generated for each share, but it should be reviewed alongside share count changes, margins, cash flow, and valuation metrics.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.